About Newron Pharmaceuticals
Newron Pharmaceuticals is a company based in Milan (Italy) founded in 1999.. Newron Pharmaceuticals has raised $54.94 million across 10 funding rounds from investors including Apax Partners, European Investment Bank and 3i Group. Newron Pharmaceuticals offers products and services including Xadago and Evenamide. Newron Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Reunion Neuroscience, Cerecor and Neurovance, among others.
- Headquarter Milan, Italy
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Newron Pharmaceuticals S.P.A.
-
Annual Revenue
$54.03 M (USD)456.35as on Dec 31, 2024
-
Net Profit
$16.66 M (USD)0as on Dec 31, 2024
-
EBITDA
$27.73 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$54.94 M (USD)
in 10 rounds
-
Latest Funding Round
$45.94 M (USD), Debt – Conventional
Jun 28, 2019
-
Investors
Apax Partners
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Newron Pharmaceuticals
Newron Pharmaceuticals is a publicly listed company on the SIX with ticker symbol NWRN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Newron Pharmaceuticals
Newron Pharmaceuticals offers a comprehensive portfolio of products and services, including Xadago and Evenamide. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for Parkinson's disease in CNS disorders
Add-on therapy for schizophrenia patients
Unlock access to complete
Unlock access to complete
Funding Insights of Newron Pharmaceuticals
Newron Pharmaceuticals has successfully raised a total of $54.94M across 10 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $45.94 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Debt – Conventional — $45.9M
-
First Round
First Round
(24 Apr 2002)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Debt – Conventional - Newron Pharmaceuticals | Valuation |
investors |
|
| Sep, 2017 | Amount | Post-IPO - Newron Pharmaceuticals | Valuation |
investors |
|
| Oct, 2016 | Amount | Post-IPO - Newron Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Newron Pharmaceuticals
Newron Pharmaceuticals has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Apax Partners, European Investment Bank and 3i Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on company buyouts
|
Founded Year | Domain | Location | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Newron Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Newron Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Newron Pharmaceuticals Comparisons
Competitors of Newron Pharmaceuticals
Newron Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Reunion Neuroscience, Cerecor and Neurovance, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Newron Pharmaceuticals
Frequently Asked Questions about Newron Pharmaceuticals
When was Newron Pharmaceuticals founded?
Newron Pharmaceuticals was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Where is Newron Pharmaceuticals located?
Newron Pharmaceuticals is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Who is the current CEO of Newron Pharmaceuticals?
Anders Haegerstrand is the current CEO of Newron Pharmaceuticals.
Is Newron Pharmaceuticals a funded company?
Newron Pharmaceuticals is a funded company, having raised a total of $54.94M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $26.99M, raised on Apr 24, 2002.
What is the annual revenue of Newron Pharmaceuticals?
Annual revenue of Newron Pharmaceuticals is $54.03M as on Dec 31, 2024.
What does Newron Pharmaceuticals do?
Newron Pharmaceuticals was founded in 1999 and is headquartered in Milan, Italy. Operations focus on the pharmaceutical sector, with a pipeline of drug candidates targeted at central nervous system disorders and pain conditions. Key candidates include Xadago for Parkinsons disease treatment, Evenamide for schizophrenia symptoms, Sarizotan for Rett syndrome, and ralfinamide for rare pain indications. Development efforts are directed toward unmet medical needs in neurology.
Who are the top competitors of Newron Pharmaceuticals?
Newron Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Seaport Therapeutics.
What products or services does Newron Pharmaceuticals offer?
Newron Pharmaceuticals offers Xadago and Evenamide.
Is Newron Pharmaceuticals publicly traded?
Yes, Newron Pharmaceuticals is publicly traded on SIX under the ticker symbol NWRN.
Who are Newron Pharmaceuticals's investors?
Newron Pharmaceuticals has 8 investors. Key investors include Apax Partners, European Investment Bank, 3i Group, Atlas Venture, and HBM Healthcare Investments.
What is Newron Pharmaceuticals's ticker symbol?
The ticker symbol of Newron Pharmaceuticals is NWRN on SIX.